Global Real-world Evidence Solutions Market on Track for 10% CAGR Driven by Regulatory Backing by 2030
The real-world
evidence (RWE) solutions market is expected to expand at a
CAGR of ~10% during the forecast period. Key factors driving this
growth include increasing regulatory support for RWE adoption, the rising
incidence of chronic diseases, increased investment from pharmaceutical
companies, the growing focus on personalized medicine and targeted therapies,
the widespread adoption of electronic health records (EHRs) and digital health
data, and the potential of RWE to lower drug development costs and enhance the
efficiency of clinical trials.
Real-world evidence (RWE) solutions refer to advanced
analytical tools, platforms, and methodologies that leverage real-world data
(RWD) to generate clinical insights on the usage, effectiveness, safety, and
value of medical products, treatments, and healthcare interventions. These
solutions integrate data from various sources including electronic
health records (EHRs), claims databases, patient registries, wearable
devices, and patient-reported outcomes to support drug development, regulatory
decision-making, market access, post-market surveillance, and value-based
healthcare initiatives. RWE solutions help pharmaceutical companies, healthcare
providers, payers, and regulatory bodies assess treatment outcomes, improve
patient care, optimize clinical practices, and inform reimbursement and policy
decisions. Real-world evidence (RWE) has been in use for decades, but recent
advances in digital technology and advanced analytics allow it to be employed
in new ways.
🔗 Want deeper insights?
Download the sample report:
https://meditechinsights.com/real-world-evidence-solutions-market/request-sample/
RWE plays a vital role in helping regulators formulate
decisions
RWE could potentially help the FDA while making regulatory
decisions about the safety and effectiveness of medical products such as
identifying new safety issues post-approval or determining the effectiveness of
a drug for a new indication or patient population. Unlike traditional clinical
trials, which are conducted in controlled environments with limited patient
populations, RWE provides insights from diverse patient groups, routine
clinical practice, and post-market surveillance. This enables regulators to
evaluate treatment outcomes, monitor adverse events, and refine drug labeling
based on real-world usage. Additionally, RWE supports expedited approvals and
label expansions by supplementing clinical trial data, especially in areas like
rare diseases, personalized medicine, and oncology. Citing the potential, the
21st Century Cures Act (Cures Act, signed in 2016) required the FDA to
publish a framework for a program to evaluate the use of RWE in regulatory
decision-making; FDA published the framework for this program in December 2018.
As part of its RWE Program, the FDA committed to understanding the full
potential of RWD and RWE in regulatory decision-making. The agency has been
holding workshops, funding demonstration projects, creating mobile and web applications
that can collect RWD, and engaging with sponsors on the topic.
Pharma/biopharma companies are focusing on strengthening
RWE capabilities
The ability to rapidly convert real-world data sources, such
as claims data and electronic medical records (EMRs), into actionable evidence
enhances patient health outcomes by enabling pharmaceutical companies to
streamline drug development and optimize commercialization strategies. These
insights empower biopharmaceutical firms to accelerate the
development of effective therapies, generate robust evidence for payers, and
strengthen their competitive positioning in the healthcare market. To access
high-quality real-world data and refine study designs, many pharma companies
are establishing strategic collaborations with healthcare providers, payers,
and data analytics firms. Enhancing RWE capabilities also allows them to adapt
to the growing focus on value-based care and reimbursement models, ensuring
that new treatments align with both regulatory and payer expectations.
Consequently, the industry is shifting toward integrated RWE platforms,
real-time evidence generation, and adaptive trial designs, reinforcing RWE as a
key driver of innovation and improved patient outcomes.
Competitive Landscape Analysis
The global real-world evidence (RWE) solutions market is
marked by the presence of established and emerging market players such as IQVIA
Holdings; Parexel; Icon; PPD; Syneos Health; Clarivate; Cerner; Medpace
Holdings; Flatiron Health; Symphony Innovation; Aetion; Cognizant
Technology; IBM; Oracle; Data Matrix; SAS Institute Inc.; Clinigen Group; and
UnitedHealth Group; among others. Some of the key strategies adopted
by market players include new product development, strategic partnerships and
collaborations, and investments.
Gain a competitive edge-request a
sample report now!
https://meditechinsights.com/real-world-evidence-solutions-market/request-sample/
Global Real-world Evidence (RWE) Solutions Market
Segmentation
This report by Medi-Tech Insights provides the size of
the global real-world evidence (RWE) solutions market at the regional- and
country-level from 2023 to 2030. The report further segments the market based
on component, application, and end user.
Market Size & Forecast (2023-2030), By Component, USD
Million
- Services
- Data
Sets
- Claims
Data
- Clinical
Settings Data
- Patient-Powered
Data
- Pharmacy
Data
Market Size & Forecast (2023-2030), By Application,
USD Million
- Drug
development & approvals
- Medical
device development & approvals
- Post-market
safety & adverse events monitoring
- Reimbursement/coverage
and regulatory decision making
Market Size & Forecast (2023-2030), By End User, USD
Million
- Healthcare
Companies (Pharmaceutical, Biopharmaceutical, Medical Devices)
- Healthcare
Payers
- Healthcare
Providers
- Others
Market Size & Forecast (2023-2030), By Region, USD
Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive intelligence,
market sizing and forecasting, pricing analysis & go-to-market strategy.
Our methodology includes rigorous secondary research combined with deep-dive
interviews with industry-leading CXO, VPs, and key demand/supply side
decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment